research Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
Topical finasteride is an effective and safer treatment for male hair loss.
Search
forResearch
5 / 1000+ results
research Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial
Low-dose dutasteride effectively and safely promotes hair growth in men.
research The Role of Topical Finasteride in Hair Loss Management: Current Evidence and Future Perspectives
Topical finasteride might help with male hair loss with fewer side effects than pills, but more research is needed.
research A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam Versus Vehicle in Women With Female Pattern Hair Loss.
5% minoxidil foam is effective and safe for hair regrowth in women with hair loss.
research Effects of Dehydroepiandrosterone Therapy on Pubic Hair Growth and Psychological Well-Being in Adolescent Girls and Young Women with Central Adrenal Insufficiency: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial
DHEA treatment helps grow pubic hair and boosts mood in girls with adrenal issues.
Community Join
5 / 1000+ resultscommunity Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community First patient dosed with Pyrilutamide (Kintor) Phase III
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
Learn
1 / 801 resultslearn Overview
Clinics
6 / 13 results- 24SMPMicroblading Antonio IIIIztacalco, Mexico City · MX
- 30
TrichologySaúde Shalon l DNA Vital ClinicalCampinas, SP · BR - 43
Hair Loss TreatmentsNIOLANAI Institute of Clinical Cosmetology and TrichologyMumbai, Maharashtra · IN - 8
Hair Loss TreatmentsCatalyst Medical Center + Clinical SpaFargo, ND · US - 22
TrichologyHair TransplantCLINICAL HAIR&HEALTHOstrava · CZ - 29
Hair TransplantHair Loss TreatmentsClinical BédardMontréal, QC · CA
